Can an herbal formula boost lung cancer treatment?
NCT ID NCT07390565
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding Yishen Qutong Granules, a traditional Chinese medicine, to standard chemo-immunotherapy can improve outcomes for people with extensive-stage small cell lung cancer. About 308 participants will receive either the herbal granules or a placebo alongside their regular treatment. The goal is to see if the granules help control the disease, improve quality of life, and reduce side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Yishen Qutong Granules (a traditional Chinese medicine formula)
- What this could lead to
- If it works, this could offer a way to reduce chemotherapy side effects and improve quality of life and survival for people with advanced small cell lung cancer.
- What could go wrong
- This is an early-stage trial with no phase designation, so results are uncertain. The herbal granules may not provide added benefit over standard therapy, and interactions with chemo-immunotherapy are not well understood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 308 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Meets Western medical diagnostic criteria for extensive-stage small cell lung cancer and Chinese medicine diagnostic criteria for kidney deficiency with qi deficiency and stagnation of blood stasis; * Newly diagnosed extensive-stage small cell lung cancer patients who have not previously received Western medical antineoplastic therapy, with evaluable lesions; * Intended to receive ≥2 cycles of first-line immunotherapy plus platinum-based chemotherapy plus etoposide; * No concurrent or prior history of other primary malignancies; * Aged ≥18 years with an estimated survival period of ≥3 months; * Karnofsky Performance Status (KPS) ≥60 points; * Normal cognitive function sufficient to complete questionnaires; * Voluntary acceptance of the study treatment regimen and signing of informed consent. Exclusion Criteria: * Pregnant or breastfeeding women, or individuals with severe diseases affecting the cardiovascular, pulmonary, hepatic, renal, or haematological systems; * Participants in other clinical trials.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Extensive-stage small cell lung cancer (SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College
Beijing, Chaoyang, 100021, China